# US 8,277,810 B2 · Antagonist anti-CD40 antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,810 B2
- Document ID: US8277810B2
- Status: Granted
- Kind: B2
- Application number: 11/932,472
- Filed: 2007-10-31
- Published: 2008-10-16
- Granted: 2012-10-02
- Earliest claimed: 2003-11-04
- Assignees: Novartis Vaccines and Diagnostics, Inc.
- Inventors: Li Long; Mohammad Luqman; Asha Yabannavar; Isabel Zaror; Bao-Lu Chen; Xiaofeng Lu; Sang Hoon Lee; Deborah Hurst
- Web page: https://patentgrep.com/patent/US8277810B2

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/06: Antiasthmatics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/14: for RNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/21: from primates, e.g. man
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.

## Claims

### Claim 1

A human monoclonal antibody that is capable of specifically binding to human CD40 expressed on the surface of a human CD40-expressing cell, said monoclonal antibody being free of significant agonist activity, whereby, when said monoclonal antibody binds to CD40 expressed on the surface of said cell, the growth or differentiation of said cell is inhibited, wherein said antibody is selected from the group consisting of:
a) the monoclonal antibody CHIR-12.12 produced by the hybridoma cell line deposited with the ATCC as Patent Deposit No. PTA-5543;
b) a monoclonal antibody comprising a light chain variable domain comprising residues 21-132 of SEQ ID NO:2;
c) a monoclonal antibody comprising a heavy chain variable domain comprising residues 20-139 of SEQ ID NO:4;
d) a monoclonal antibody comprising an amino acid sequence selected from the group consisting of:
(i) residues 21-239 of SEQ ID NO:2;
(ii) SEQ ID NO:2;
(iii) residues 20-469 of SEQ ID NO:4;
(iv) SEQ ID NO:4;
(v) residues 20-469 of SEQ ID NO:5;
(vi) SEQ ID NO:5;
(vii) residues 21-132 of SEQ ID NO:2 and residues 20-139 of SEQ ID NO:4;
(viii) residues 21-239 of SEQ ID NO:2 and residues 20-469 of SEQ ID NO:4;
(ix) residues 21-239 of SEQ ID NO:2 and residues 20-469 of SEQ ID NO:5;
(x) SEQ ID NO:2 and SEQ ID NO:4; and
(xi) SEQ ID NO:2 and SEQ ID NO:5;
e) a monoclonal antibody that is an antigen-binding fragment of a monoclonal antibody of any one of preceding items a)-d), wherein said fragment retains the capability of specifically binding to said human CD40, and wherein said fragment is selected from the group consisting of a Fab fragment, an F(ab′)2 fragment, an Fv fragment, and a single-chain Fv fragment; and
f) a conjugated form of the monoclonal antibody of any one of preceding items a)-e).

### Claim 2 (depends on 1)

A monoclonal antibody according to claim 1, wherein said antibody is produced in a CHO cell line.

### Claim 3 (depends on 1)

A hybridoma cell line capable of producing the monoclonal antibody according to claim 1.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising the monoclonal antibody of claim 1.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein said composition is a liquid pharmaceutical formulation comprising a buffer in an amount to maintain the pH of the formulation in a range of about pH 5.0 to about pH 7.0.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, wherein said formulation further comprises an isotonizing agent in an amount to render same composition near isotonic.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein said isotonizing agent is sodium chloride, said sodium chloride being present in said formulation at a concentration of about 50 mM to about 300 mM.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein said sodium chloride is present is said formulation at a concentration of about 150 mM.

### Claim 9 (depends on 5)

The pharmaceutical composition of claim 5, wherein said buffer is selected from the group consisting of succinate, citrate, and phosphate buffers.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein said formulation comprises said buffer at a concentration of about 1 mM to about 50 mM.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, wherein said buffer is sodium succinate or sodium citrate at a concentration of about 5 mM to about 15 mM.

### Claim 12 (depends on 5)

The pharmaceutical composition of claim 5, wherein said formulation further comprises a surfactant in an amount from about 0.001% to about 1.0%.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein said surfactant is polysorbate 80, which is present in said formulation in an amount from about 0.001% to about 0.5%.

### Claim 14

A human monoclonal antibody that is capable of specifically binding to human CD40 expressed on the surface of a human CD40-expressing cell, said monoclonal antibody being free of significant agonist activity, whereby, when said monoclonal antibody binds to CD40 expressed on the surface of said cell, the growth or differentiation of said cell is inhibited, wherein said antibody is selected from the group consisting of:
a) a monoclonal antibody comprising a light chain variable domain containing the complementarity determining region (CDR) residues of SEQ ID NO:2, and a heavy chain variable domain containing the complementarity determining region (CDR) residues of SEQ ID NO:4; and
b) a monoclonal antibody comprising the complementarity determining regions (CDRs) of the monoclonal antibody CHIR-12.12 produced by the hybridoma cell line deposited with the ATCC as Patent Deposit No. PTA-5543.

### Claim 15 (depends on 14)

A conjugated form of the monoclonal antibody of claim 14.

### Claim 16 (depends on 14)

An antigen-binding fragment of the monoclonal antibody of claim 14, wherein said fragment retains the capability of specifically binding to said human CD40.

### Claim 17 (depends on 14)

A pharmaceutical composition comprising the monoclonal antibody of claim 14.

### Claim 18

A human monoclonal antibody that is capable of specifically binding to human CD40 expressed on the surface of a human CD40-expressing cell, said monoclonal antibody being free of significant agonist activity, whereby, when said monoclonal antibody binds to CD40 expressed on the surface of said cell, the growth or differentiation of said cell is inhibited, wherein said antibody is the monoclonal antibody CHIR-12.12 produced by the hybridoma cell line deposited with the ATCC as Patent Deposit No. PTA-5543 or an antigen-binding fragment thereof, wherein said fragment retains the capability of specifically binding to said human CD40.

### Claim 19 (depends on 18)

The monoclonal antibody of claim 18, wherein said antigen-binding fragment is selected from the group consisting of a Fab fragment, an F(ab′), fragment, an Fv fragment, and a single-chain Fv fragment.

### Claim 20 (depends on 18)

A conjugated form of the monoclonal antibody or antigen-binding fragment of claim 18.

### Claim 21 (depends on 18)

A pharmaceutical composition comprising the monoclonal antibody or antigen-binding fragment of claim 18.

### Claim 22

A human monoclonal antibody that is capable of specifically binding to human CD40 expressed on the surface of a human CD40-expressing cell, said monoclonal antibody being free of significant agonist activity, whereby, when said monoclonal antibody binds to CD40 expressed on the surface of said cell, the growth or differentiation of said cell is inhibited, wherein said antibody comprises:
a) residues 21-132 of SEQ ID NO:2 and residues 20-139 of SEQ ID NO:4;
b) residues 21-239 of SEQ ID NO:2 and residues 20-469 of SEQ ID NO:4; or
c) residues 21-239 of SEQ ID NO:2 and residues 20-469 of SEQ ID NO:5.

### Claim 23 (depends on 22)

A conjugated form of the monoclonal antibody of claim 22.

### Claim 24 (depends on 22)

A pharmaceutical composition comprising the monoclonal antibody of claim 22.

### Claim 25

A human monoclonal antibody that is capable of specifically binding to human CD40 expressed on the surface of a human CD40-expressing cell, said monoclonal antibody being free of significant agonist activity, whereby, when said monoclonal antibody binds to CD40 expressed on the surface of said cell, the growth or differentiation of said cell is inhibited, wherein said antibody is selected from the group consisting of:
a) the monoclonal antibody CHIR-5.9 produced by the hybridoma cell line deposited with the ATCC as Patent Deposit No. PTA-5542;
b) a monoclonal antibody comprising a light chain variable domain comprising residues 21-132 of SEQ ID NO:6;
c) a monoclonal antibody comprising a heavy chain variable domain comprising residues 20-144 of SEQ ID NO:7;
d) a monoclonal antibody comprising an amino acid sequence selected from the group consisting of:
(i) residues 21-239 of SEQ ID NO:6;
(ii) SEQ ID NO:6;
(iii) residues 20-474 of SEQ ID NO:7;
(iv) SEQ ID NO:7;
(v) residues 20-474 of SEQ ID NO:8;
(vi) SEQ ID NO:8;
(vii) residues 21-132 of SEQ ID NO:6 and residues 20-144 of SEQ ID NO:7;
(viii) residues 21-239 of SEQ ID NO:6 and residues 20-474 of SEQ ID NO:7;
(ix) residues 21-239 of SEQ ID NO:6 and residues 20-474 of SEQ ID NO:8;
(x) SEQ ID NO:6 and SEQ ID NO:7; and
(xi) SEQ ID NO:6 and SEQ ID NO:8;
e) a monoclonal antibody that is an antigen-binding fragment of a monoclonal antibody of any one of preceding items a)-d), wherein said fragment retains the capability of specifically binding to said human CD40, and wherein said fragment is selected from the group consisting of a Fab fragment, an F(ab′)2 fragment, an Fv fragment, and a single-chain Fv fragment; and
f) a conjugated form of the monoclonal antibody of any one of preceding items a)-e).

### Claim 26 (depends on 25)

A monoclonal antibody according to claim 25, wherein said antibody is produced in a CHO cell line.

### Claim 27 (depends on 25)

A hybridoma cell line capable of producing the monoclonal antibody according to claim 25.

### Claim 28 (depends on 25)

A pharmaceutical composition comprising the monoclonal antibody of claim 25.

### Claim 29 (depends on 28)

The pharmaceutical composition of claim 28, wherein said composition is a liquid pharmaceutical formulation comprising a buffer in an amount to maintain the pH of the formulation in a range of about pH 5.0 to about pH 7.0.

### Claim 30 (depends on 29)

The pharmaceutical composition of claim 29, wherein said formulation further comprises an isotonizing agent in an amount to render same composition near isotonic.

### Claim 31 (depends on 30)

The pharmaceutical composition of claim 30, wherein said isotonizing agent is sodium chloride, said sodium chloride being present in said formulation at a concentration of about 50 mM to about 300 mM.

### Claim 32 (depends on 31)

The pharmaceutical composition of claim 31, wherein said sodium chloride is present is said formulation at a concentration of about 150 mM.

### Claim 33 (depends on 29)

The pharmaceutical composition of claim 29, wherein said buffer is selected from the group consisting of succinate, citrate, and phosphate buffers.

### Claim 34 (depends on 33)

The pharmaceutical composition of claim 33, wherein said formulation comprises said buffer at a concentration of about 1 mM to about 50 mM.

### Claim 35 (depends on 34)

The pharmaceutical composition of claim 34, wherein said buffer is sodium succinate or sodium citrate at a concentration of about 5 mM to about 15 mM.

### Claim 36 (depends on 29)

The pharmaceutical composition of claim 29, wherein said formulation further comprises a surfactant in an amount from about 0.001% to about 1.0%.

### Claim 37 (depends on 36)

The pharmaceutical composition of claim 36, wherein said surfactant is polysorbate 80, which is present in said formulation in an amount from about 0.001% to about 0.5%.

### Claim 38

A human monoclonal antibody that is capable of specifically binding to human CD40 expressed on the surface of a human CD40-expressing cell, said monoclonal antibody being free of significant agonist activity, whereby, when said monoclonal antibody binds to CD40 expressed on the surface of said cell, the growth or differentiation of said cell is inhibited, wherein said antibody is selected from the group consisting of:
a) a monoclonal antibody comprising a light chain variable domain containing the complementarity determining region (CDR) residues of SEQ ID NO:6, and a heavy chain variable domain containing the complementarity determining region (CDR) residues of SEQ ID NO:7; and
b) a monoclonal antibody comprising the complementarity determining regions (CDRs) of the monoclonal antibody CHIR-5.9 produced by the hybridoma cell line deposited with the ATCC as Patent Deposit No. PTA-5542.

### Claim 39 (depends on 38)

A conjugated form of the monoclonal antibody of claim 38.

### Claim 40 (depends on 38)

An antigen-binding fragment of the monoclonal antibody of claim 38, wherein said fragment retains the capability of specifically binding to said human CD40.

### Claim 41 (depends on 38)

A pharmaceutical composition comprising the monoclonal antibody of claim 38.

### Claim 42

A human monoclonal antibody that is capable of specifically binding to human CD40 expressed on the surface of a human CD40-expressing cell, said monoclonal antibody being free of significant agonist activity, whereby, when said monoclonal antibody binds to CD40 expressed on the surface of said cell, the growth or differentiation of said cell is inhibited, wherein said antibody is the monoclonal antibody CHIR-5.9 produced by the hybridoma cell line deposited with the ATCC as Patent Deposit No. PTA-5542 or an antigen-binding fragment thereof, wherein said fragment retains the capability of specifically binding to said human CD40.

### Claim 43 (depends on 42)

The monoclonal antibody of claim 42, wherein said antigen-binding fragment is selected from the group consisting of a Fab fragment, an F(ab′)2 fragment, an Fv fragment, and a single-chain Fv fragment.

### Claim 44 (depends on 42)

A conjugated form of the monoclonal antibody or antigen-binding fragment of claim 42.

### Claim 45 (depends on 42)

A pharmaceutical composition comprising the monoclonal antibody or antigen-binding fragment of claim 42.

### Claim 46

A human monoclonal antibody that is capable of specifically binding to human CD40 expressed on the surface of a human CD40-expressing cell, said monoclonal antibody being free of significant agonist activity, whereby, when said monoclonal antibody binds to CD40 expressed on the surface of said cell, the growth or differentiation of said cell is inhibited, wherein said antibody comprises:
a) residues 21-132 of SEQ ID NO:6 and residues 20-144 of SEQ ID NO:7;
b) residues 21-239 of SEQ ID NO:6 and residues 20-474 of SEQ ID NO:7; or
c) residues 21-239 of SEQ ID NO:6 and residues 20-474 of SEQ ID NO:8.

### Claim 47 (depends on 46)

A conjugated form of the monoclonal antibody of claim 46.

### Claim 48 (depends on 46)

A pharmaceutical composition comprising the monoclonal antibody of claim 46.

### Claim 49

A hybridoma cell line capable of producing a monoclonal antibody that is capable of specifically binding to human CD40 expressed on the surface of a human CD40-expressing cell, wherein said hybridoma cell line is the cell line deposited with the ATCC as Patent Deposit No. PTA-5543.

### Claim 50

A hybridoma cell line capable of producing a monoclonal antibody that is capable of specifically binding to human CD40 expressed on the surface of a human CD40-expressing cell, wherein said hybridoma cell line is the cell line deposited with the ATCC as Patent Deposit No. PTA-5542.
